Nektar begins Phase 2 study of NKTR-181
The double-blind, placebo-controlled trial is designed to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The certification was based on the MedicsDocAssistant’s interoperability and interconnectivity with DHIN’s various data senders. DHIN’s various data sender healthcare companies include BayHealth Medical Center, Beebe Medical Center,
The companies will leverage and build upon EnviroLogix isothermal DNAblev2.0 chemistry and Douglas Scientific’s disruptive Array Tape Platform. Douglas Scientific president and COO Dan Malmstrom said the substantial